Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-09
Donald Joseph Johann
Federal Grant PI
High Impact
Professor
Also affiliated: MetroHealth (1996); National Institutes of Health (2004–2013); United States Food and Drug Administration (2004); George Mason University (2006); Fudan University (2021); University of Michigan (2010); University of Arkansas Medical Center (2018–2024); Shanghai Cancer Institute (2021); Eastern Association for the Surgery of Trauma (1996); Michigan Medicine (2010); Frederick National Laboratory for Cancer Research (2007–2010); National Cancer Institute (2004–2013); Center for Cancer Research (2004–2012); MetroHealth Medical Center (1996); Division of Cancer Epidemiology and Genetics (2008); State Key Laboratory of Genetic Engineering (2021); University of Oklahoma Health Sciences Center (2006); Case Western Reserve University (1996); University of Nebraska Medical Center (2006); Science Applications International Corporation (United States) (2010)
Biomedical Informatics, College of Medicine
23 h-index
117 pubs
2,560 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Donald J. Johann's research focuses on the application of high-throughput sequencing and mass spectrometry techniques to study cancer biomarkers, particularly circulating tumor DNA (ctDNA) for precision oncology and liquid biopsy applications. His work investigates the analytical validity and performance of these assays, aiming to advance the measurement of actionable mutations in ctDNA. This research is supported by a $750,000 NIH/National Institute of General Medical Sciences grant for an advanced next-generation sequencer.
Johann has published extensively on topics related to cancer genomics, including the assessment of oncopanels for detecting small variants and the quality control of next-generation sequencing (NGS) data. His scholarship includes 117 publications with over 2,400 citations, and an h-index of 23. He collaborates with researchers at the University of Arkansas for Medical Sciences and the National Center for Toxicological Research, with whom he has co-authored multiple publications.
His group's work contributes to the development and validation of molecular diagnostic tools for cancer. Recent publications also explore related areas such as the role of exogenous phosphatidic acid in acetaminophen-induced liver injury in mice and the expansion of human papillomavirus-specific T cells in a therapeutic vaccine recipient.
Metrics
- h-index: 23
- Publications: 117
- Citations: 2,560
Positions
-
Professor 2012–presentUniversity of Arkansas for Medical Sciences Biomedical Informatics, College of Medicine Institutional directory
Selected Publications
-
Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based Circulating Tumor DNA Assays, Version 2.0 (2026)
-
Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer's Molecular Residual Disease Analytical Validation Working Group Consensus Recommendation (2026)
-
Lexicon for Clonal Hematopoiesis in Liquid Biopsy (2025)
-
Harnessing Native-Resolution 2D Embeddings for Lung Cancer Classification: A Feasibility Study with the RAD-DINO Self-supervised Foundation Model (2025)
-
EET-Based Therapeutics Mitigate Sorafenib-Associated Glomerular Cell Damage (2025)
-
Augmenting precision medicine via targeted RNA-Seq detection of expressed mutations (2025)
-
Recommended Clinical Context and Patient Context Data Elements for Liquid Biopsy Data Submitted to Data Repositories and Data Commons (2025)
-
Towards Preanalytical Best Practices for Liquid Biopsy Studies: A BLOODPAC Landscape Analysis (2024)
-
Targeted DNA-seq and RNA-seq of Reference Samples with Short-read and Long-read Sequencing (2024)
-
A Microdissection Protocol for Proteogenomic Analysis of Histological Sections to Advance Drug Development (2024)
-
Advancing drug development by leveraging microdissection for proteogenomic analysis of histological sections. (2024)
-
Abstract PO5-02-05: Assessing Vaccine-Mediated Cellular Immune Responses in Patients Receiving Combined Vaccine and Chemotherapy Treatment (2024)
-
Assessments of tumor mutational burden estimation by targeted panel sequencing: A comprehensive simulation analysis (2023)
-
Liquid biopsy based on circulating tumor DNA for lung cancer: A step toward prevention (2023)
-
Contrived Materials and a Data Set for the Evaluation of Liquid Biopsy Tests (2023)
Federal Grants 1 $750,000 total
NIH
Contact PI
Jun 2024 - Jun 2025
Grants & Funding
As listed on this researcher's institutional profile. Federal awards with verified records are shown above.
- Scientific and methodological advancement in liquid biopsies to further the development of lung cancer-based precision medicine (Bio 3) U.S. Food and Drug Administration via Arkansas Research Alliance Principal Investigator
- Development and Validation of a Microdissection Method to Advance Precision Medicine in the Clinical Setting - Continuation - Continuation NIH/Nat. Cancer Institute Principal Investigator
- Financial Support for the Breast Cancer Intergroup Correlative Science Studies Breast Cancer Research Foundation via University of Michigan Principal Investigator
- Center for Studies of Host Response to Cancer Therapy NIH Co-Investigator
- Scientific and methodological advancement in liquid biopsies to further the development of lung cancer-based precision medicine U.S. Food and Drug Administration via Arkansas Research Alliance Principal Investigator
Collaboration Network
Top Collaborators
Christoph Heuck
University of Arkansas for Medical Sciences (US)
24 shared publications
- Patterns of Central Nervous System Involvement in Relapsed and Refractory Multiple Myeloma
- Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease
- Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma
- Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma
- Towards the integration, annotation and association of historical microarray experiments with RNA-seq
Showing 5 of 24 shared publications
Erich A. Peterson
Winthrop Rockefeller Foundation
23 shared publications
In database
- Liquid biopsy and its role in an advanced clinical trial for lung cancer
- Exogenous phosphatidic acid reduces acetaminophen-induced liver injury in mice by activating hepatic interleukin-6 signaling through inter-organ crosstalk
- Towards the integration, annotation and association of historical microarray experiments with RNA-seq
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- Enhancing cancer clonality analysis with integrative genomics
Showing 5 of 23 shared publications
Frits van Rhee
University of Arkansas for Medical Sciences
21 shared publications
In database
- Patterns of Central Nervous System Involvement in Relapsed and Refractory Multiple Myeloma
- Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease
- Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma
- Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma
- High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance
Showing 5 of 21 shared publications
Bart Barlogie
University of Arkansas for Medical Sciences
20 shared publications
In database
- Patterns of Central Nervous System Involvement in Relapsed and Refractory Multiple Myeloma
- Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease
- Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma
- Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma
- High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance
Showing 5 of 20 shared publications
Joshua Epstein
University of Arkansas for Medical Sciences (US)
13 shared publications
- Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease
- Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma
- Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma
- High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance
- Multiple Myeloma Cells Modulate ICAM-3 To Evade Natural Killer Cell-Mediated Lysis
Showing 5 of 13 shared publications
Maurizio Zangari
University of Arkansas for Medical Sciences
11 shared publications
In database
- Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease
- Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma
- High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance
- Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling
- Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma
Showing 5 of 11 shared publications
Gareth J. Morgan
University of Arkansas for Medical Sciences (US)
11 shared publications
- Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma
- Enhancing cancer clonality analysis with integrative genomics
- High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance
- Characterization of the Mutational Landscape of Multiple Myeloma Using Comprehensive Genomic Profiling
- Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma
Showing 5 of 11 shared publications
Rebecca Kusko
11 shared publications
- Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
- A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency
- Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions
- Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA
- Deep oncopanel sequencing reveals within block position-dependent quality degradation in FFPE processed samples
Showing 5 of 11 shared publications
Sarah Waheed
University of Arkansas for Medical Sciences (US)
10 shared publications
- Patterns of Central Nervous System Involvement in Relapsed and Refractory Multiple Myeloma
- Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease
- Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma
- The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM
- Investigation Of The Genetic Disparities Between African Americans and Causasians Utilizing Gene Expression Profiles (GEP) Of Purified Plasma Cells (PC) and Whole Bone Marrow Biopsies (BMBx)
Showing 5 of 10 shared publications
Shweta S. Chavan
University of Arkansas for Medical Sciences (US)
10 shared publications
- Towards the integration, annotation and association of historical microarray experiments with RNA-seq
- Enhancing cancer clonality analysis with integrative genomics
- Revealing the inherent heterogeneity of human malignancies by variant consensus strategies coupled with cancer clonal analysis
- High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance
- Multiple Myeloma Cells Modulate ICAM-3 To Evade Natural Killer Cell-Mediated Lysis
Showing 5 of 10 shared publications
Binsheng Gong
National Center for Toxicological Research
10 shared publications
In database
- Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
- A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency
- Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions
- Deep oncopanel sequencing reveals within block position-dependent quality degradation in FFPE processed samples
- Ultra-deep sequencing data from a liquid biopsy proficiency study demonstrating analytic validity
Showing 5 of 10 shared publications
Natalia Novoradovskaya
Agilent Technologies (United States) (US)
10 shared publications
- Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
- A verified genomic reference sample for assessing performance of cancer panels detecting small variants of low allele frequency
- Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions
- Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA
- Deep oncopanel sequencing reveals within block position-dependent quality degradation in FFPE processed samples
Showing 5 of 10 shared publications
Michael Bauer
University of Arkansas for Medical Sciences
9 shared publications
In database
- Towards the integration, annotation and association of historical microarray experiments with RNA-seq
- Enhancing cancer clonality analysis with integrative genomics
- Revealing the inherent heterogeneity of human malignancies by variant consensus strategies coupled with cancer clonal analysis
- High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance
- Leveraging the new with the old: providing a framework for the integration of historic microarray studies with next generation sequencing
Showing 5 of 9 shared publications
Jennifer S. LoCoco
Illumina (United States) (US)
9 shared publications
- Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology
- Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions
- Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA
- Deep oncopanel sequencing reveals within block position-dependent quality degradation in FFPE processed samples
- Targeted DNA-seq and RNA-seq of Reference Samples with Short-read and Long-read Sequencing
Showing 5 of 9 shared publications
Faith E. Davies
University of Arkansas for Medical Sciences (US)
8 shared publications
- Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma
- High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance
- Targeted MEK Inhibition in Patients with Previously Treated Multiple Myeloma
- Jumping Translocations of 1q12 in Multiple Myeloma: Unexpected Intra-clonal Heterogeneity of Copy Number Aberrations in the 1q21-31 Region
- The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM
Showing 5 of 8 shared publications
Similar Researchers
Based on overlapping research topics
Binsheng Gong
National Center for Toxicological Research
Cancer Genomics and Diagnostics
Molecular Biology Techniques and Applications
Genomics and Phylogenetic Studies
Jason L. Muesse
University of Arkansas for Medical Sciences
Cancer Genomics and Diagnostics
Molecular Biology Techniques and Applications
Genomics and Phylogenetic Studies
William Newton Suter
University of Arkansas at Little Rock
Cancer Genomics and Diagnostics
Molecular Biology Techniques and Applications
Genomics and Phylogenetic Studies
James R. Lindsay
University of Arkansas at Fayetteville
Cancer Genomics and Diagnostics
Genomics and Phylogenetic Studies
Cancer Treatment and Pharmacology
Christopher P. Wardell
University of Arkansas for Medical Sciences
Cancer Genomics and Diagnostics
Molecular Biology Techniques and Applications
Genomics and Phylogenetic Studies
Julie A. Thomas
University of Arkansas at Fayetteville
Metabolomics and Mass Spectrometry Techniques
Molecular Biology Techniques and Applications
Genomics and Phylogenetic Studies